论文部分内容阅读
AIM:To investigate the seroprevalence of He/icobacterpy/oriinfection in patients with different digestive malignant tumors.METHODS:Enzyme linked immunosorbent assay (ELISA)was used to detect serum anti-Helicobacter pylori IgGantibody in 374 patients with different digestive malignanttumors and 310 healthy subjects (normal control group).RESULTS:The seroprevalence of He/icobacter pyloriinfection was 61.50%(230/374) and 46.77% (145/310),respectively,in patients with digestive tumors and normalcontrols (P<0.05).The seroprevalence was 52.38% (33/63),86.60% (84/97),83.14% (84/101),45.24 (19/42),51.13% (18/35) and 44.44% (16/36),respectively inpatients with carcinomas of esophagus,stomach,duodenum,rectum,colon and liver (P<0.01).In patients with intestinaland diffuse type gastric cancers,the seroprevalence was93.75% (60/64) and 72.73% (24/33),respectively (P<0.05).In patients with gastric antral and cardiac cancers,theseroprevalence was 96.43% (54/56) and 73.17% (30/41),respectively (P<0.05).In patients with ulcerous and proliferoustype duodenal cancers,the seroprevalence of H pyloriinfection was 91.04% (61/67) and 52.27% (23/44),respectively (P<0.05).In patients with duodenal bulb anddescending cancers,the seroprevalence was 94.20% (65/69)and 45.20% (19/42),respectively (P<0.05).CONCLUSION:Hpyloriinfection is associated with occurrenceand development of gastric and duodenal carcinomas.Furthermore,it is also associated with histological type andlocations of gastric and duodenal carcinomas.
AIM: To investigate the seroprevalence of He / icobacterpy / oriinfection in patients with different digestive malignant tumors. METHODS: Enzyme linked immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group) .RESULTS: The seroprevalence of He / icobacter pylori infection was 61.50% (230/374) and 46.77% (145/310), respectively, in patients with digestive tumors and normal controls (P <0.05) 52.38% (33/63), 86.60% (84/97), 83.14% (84/101), 45.24 (19/42), 51.13% (18/35) and 44.44% (16/36) Patients with intestinaland diffuse type gastric cancers, the seroprevalence was 93.75% (60/64) and 72.73% (24/33), respectively ( In patients with gastric antral and cardiac cancers, the seroprevalence was 96.43% (54/56) and 73.17% (30/41), respectively (P <0.05) In patients with ulcerous and proliferoustype duodenal cancers, the seroprevalence of H pylori infection was 91.04% (61/67) and 52.27% (23/44), respectively (P <0.05) .In patients with duodenal bulb and descending cancers, the seroprevalence was 94.20% (65/69) and 45.20% (19/42) respectively, respectively (P <0.05) .CONCLUSION: Hpylori infection is associated with occurrence and development of gastric and duodenal carcinomas. Frthermore, it is also associated with histological type and in of gastric and duodenal carcinomas.